Predict your next investment

Angel Investor (Individual)

See what CB Insights has to offer

Investments

4

About Peter Brabeck-Letmathe

Peter Brabeck-Letmathe Headquarter Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Peter Brabeck-Letmathe News

Swiss-backed project aims to avert new 'Cold War' in science

Oct 8, 2021

By JAMEY KEATENAssociated Press 1 of 4 Patrick Aebischer, GESDA Vice Chairman, Nanjira Sambuli, Policy Analyst and Advocacy Strategist, Kenya, Peter Brabeck-Letmathe, GESDA Chairman, Chorh Chuan Tan, Chief Health Scientist, Singapore, left and right, and Swiss Federal Councilor Ignazio Cassis on the screen in recorded video, speaks about the first Geneva Science and Diplomacy Anticipation Summit 2021 (GESDA), during a press conference at the Campus Biotech in Geneva, Switzerland, Thursday, October 07, 2021. MARTIAL TREZZINI Patrick Aebischer, GESDA Vice Chairman, Nanjira Sambuli, Policy Analyst and Advocacy Strategist, Kenya, Peter Brabeck-Letmathe, GESDA Chairman, Chorh Chuan Tan, Chief Health Scientist, Singapore, left and right, speaks about the first Geneva Science and Diplomacy Anticipation Summit 2021 (GESDA), during a press conference at the Campus Biotech in Geneva, Switzerland, Thursday, October 07, 2021. MARTIAL TREZZINI Nanjira Sambuli, Policy Analyst and Advocacy Strategist, Kenya, speaks about the first Geneva Science and Diplomacy Anticipation Summit 2021 (GESDA), during a press conference at the Campus Biotech in Geneva, Switzerland, Thursday, October 07, 2021. MARTIAL TREZZINI Chorh Chuan Tan, Chief Health Scientist, Singapore, speaks about the first Geneva Science and Diplomacy Anticipation Summit 2021 (GESDA), during a press conference at the Campus Biotech in Geneva, Switzerland, Thursday, October 07, 2021. The First Geneva Science and Diplomacy Anticipation Summit 2021 will be held at Campus Biotech, from 7 to 9 October. MARTIAL TREZZINI By JAMEY KEATENAssociated Press GENEVA (AP) — Switzerland’s foreign minister says concerns about a “new Cold War” over science and technology are a major reason behind the creation of a new think tank that looks out for future advances and development — so that the whole world can benefit, not just rich countries. Ignazio Cassis delivered a video message for the inaugural “summit” on Thursday and Friday of the Geneva Science and Diplomacy Anticipator, or GESDA, a Swiss government-backed project that aims to bridge government policy and science in an international city known for both. “There is a growing feeling that a new Cold War is about to be fought over science and technology, and the power they confer to the states that master them,” he said. GESDA, which brings together hundreds of scientists and policymakers worldwide, would serve as an “honest broker” that helps spread the benefits of science to countries rich and poor, he said. “What we are trying to achieve with GESDA is new, and hence, difficult: To link anticipation that looks far ahead, with action that is immediate is a major challenge in itself,” Cassis said. While conceived in 2019, GESDA has started to look prescient during the COVID-19 pandemic that caught many governments off guard, drew an uncertain or unclear response by health policy makers like the Geneva-based World Health Organization, and has exposed gaping inequality between the rich countries that have wide access to vaccines — and poor countries that don’t. Pandemic preparedness projects and monitoring bodies have popped up in places like Europe and the United States since the outbreak, and the Biden administration has shown interest in the GESDA project -– and its focus on anticipating future trends and developments. Alondra Nelson, deputy director for science and society for the White House Office of Science and Technology Policy, noted U.S. President Joe Biden has spoken about today’s moment “of great peril and great promise,” and she said governments should be bold about both innovation and partnership. “I think that the Anticipator — anticipatory frame — is a fantastic possibility for working this through,” she said by videoconference from Washington on Thursday. “Anticipation is filled, of course, with both enthusiasm and yet unease.” Dr. Jeremy Farrar, the director of the Wellcome Trust charity and a key player in international health policy, has lined up with GESDA and told reporters on Thursday that while science has made great strides, action must be taken because otherwise “scientific advances will increasingly be available to a small elite in the world — and not to everybody.” Last week, GESDA and XPrize announced the creation of a prize for developments in quantum computing. But GESDA, a self-dubbed “do tank,” has far broader ambitions such as helping set up a global court for scientific disputes and a Manhattan Project-style effort to rid excess carbon from the atmosphere. It brings together hundreds of U.N. officials, Nobel laureates, academics, diplomats, advocacy group representatives and members of the public. Backers include Swiss universities and Geneva-based CERN — home to a lab with the world’s largest atom smasher. Copyright 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.

Peter Brabeck-Letmathe Investments

4 Investments

Peter Brabeck-Letmathe has made 4 investments. Their latest investment was in Biologique Recherche as part of their Unattributed on October 10, 2019.

CBI Logo

Peter Brabeck-Letmathe Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/24/2019

Unattributed

Biologique Recherche

Yes

2

3/28/2018

Series C

Subscribe to see more

$99M

Subscribe to see more

10

5/23/2016

Series A

Subscribe to see more

$99M

Subscribe to see more

10

2/25/2016

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/24/2019

3/28/2018

5/23/2016

2/25/2016

Round

Unattributed

Series C

Series A

Series C

Company

Biologique Recherche

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

10

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.